一线免疫检查点阻断对比卡铂为基础化疗治疗转移性尿路上皮癌的有效性
本研究基于Flatiron Health电子健康记录数据库,回顾性纳入2017例接受一线卡铂为基础化疗(n=1530)或免疫治疗(n=487)的顺铂不耐受转移性尿路上皮癌患者,比较总生存。免疫治疗组12个月生存率低于化疗组,但36个月生存率高于化疗组;免疫治疗前12个月生存劣于化疗,12个月后生存优于化疗。
要点
- 免疫治疗组12个月OS为39.6%,低于化疗组的46.1%。
- 免疫治疗组36个月OS为28.3%,高于化疗组的13.3%。
- 前12个月免疫治疗OS劣于化疗(HR 1.37),12个月后优于化疗(HR 0.50)。
核心结论
- 在转移性尿路上皮癌中,临床医生和患者应仔细权衡化疗的短期获益与免疫治疗的长期获益。
研究设计与样本
- 回顾性队列研究,使用Flatiron Health电子健康记录衍生数据库,纳入2017例顺铂不耐受转移性尿路上皮癌患者,接受一线卡铂为基础化疗(n=1530)或免疫治疗(n=487),时间范围为2011年1月1日至2018年5月18日。
主要发现
- 倾向评分逆概率加权调整后,免疫治疗组12个月OS为39.6%(95%CI 34.0-45.3%),化疗组为46.1%(95%CI 43.4-48.8%)。
- 倾向评分逆概率加权调整后,免疫治疗组36个月OS为28.3%(95%CI 21.8-34.7%),化疗组为13.3%(95%CI 11.1-15.5%)。
- 前12个月免疫治疗对比卡铂为基础化疗的IPTW调整HR为1.37(95%CI 1.15-1.62),生存劣于化疗。
- 12个月后免疫治疗对比卡铂为基础化疗的IPTW调整HR为0.50(95%CI 0.30-0.85),生存优于化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 回顾性设计。
- 可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data compare first-line carboplatin-based chemotherapy and immune checkpoint blockade in cisplatin-ineligible metastatic urothelial carcinoma (mUC) patients. The primary evidence guiding treatment decisions was a recent Food and Drug Administration/European Medicines Agency safety alert based on emerging data from two ongoing phase III trials, reporting shorter survival in programmed death-ligand 1 (PD-L1)-negative patients receiving immunotherapy. Final results from these trials are unknown. OBJECTIVE: To compare survival in cisplatin-ineligible mUC patients receiving first-line immunotherapy versus those receiving carboplatin-based chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective cohort study of 2017 mUC patients receiving first-line carboplatin-based chemotherapy (n = 1530) or immunotherapy (n = 487) from January 1, 2011 to May 18, 2018 using the Flatiron Health electronic health record-derived database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcomes were overall survival (OS), comparing 12- and 36-mo OS, and hazard ratios before and after 12 mo. Propensity score-based inverse probability of treatment weighting (IPTW) was used to address confounding in Kaplan-Meier and Cox regression model estimates of comparative effectiveness. RESULTS AND LIMITATIONS: IPTW-adjusted OS rates in the immunotherapy group were lower at 12 mo (39.6% [95% confidence interval {CI} 34.0-45.3%] vs 46.1% [95% CI 43.4-48.8%]) but higher at 36 mo (28.3% [95% CI 21.8-34.7%] vs 13.3% [95% CI 11.1-15.5%]) relative to the chemotherapy group. Immunotherapy treatment demonstrated inferior OS during the first 12 mo relative to carboplatin-based chemotherapy (IPTW-adjusted hazard ratio [HR] 1.37, 95% CI 1.15-1.62), but superior OS beyond 12 mo (IPTW-adjusted HR 0.50, 95% CI 0.30-0.85). Limitations include retrospective design and potential unmeasured confounding. CONCLUSIONS: In the setting of mUC, clinicians and patients should carefully consider how to balance the short-term benefit of chemotherapy against the long-term benefit of immunotherapy. PATIENT SUMMARY: To determine the optimal first-line therapy for metastatic bladder cancer patients who are unfit for cisplatin, we compared carboplatin-based chemotherapy versus immunotherapy using real-world data. Survival in the 1st year of treatment was lower with immunotherapy relative to chemotherapy, but for patients surviving beyond the 1st year, immunotherapy was superior.
引用
- Feld E, Harton J, Meropol NJ, et al. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. Eur Urol. 2019. PMID: 31362898. doi:10.1016/j.eururo.2019.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。